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Abstract
Background:  Pro-inﬂammatory  cytokines  play  an  important  role  in  diabetic  retinopathy.  There
is conﬂicting  evidence  about  their  serum  elevation  in  this  condition  and  that  they  also  may  be
possible serum  inﬂammatory  biomarkers  of  diabetic  retinopathy.
Objective:  To  evaluate  the  presence  of  serum  pro-inﬂammatory  cytokines  and  acute  phase
reactants  in  the  serum  of  patients  with  and  without  diabetic  retinopathy.
Material  and  methods: Comparative  case  series  with  36  patients  divided  into  three  groups  were
included: 12  patients  with  diabetes  mellitus  and  diabetic  retinopathy  (group  1),  12  diabetic
patients  without  diabetic  retinopathy  (group  2),  and  12  healthy  patients  as  a  control  group.
Serum levels  of  the  following  pro-inﬂammatory  cytokines  were  measured  in  all  patients:  TNF-
, IL-1  and  IL-6.  Pro-inﬂammatory  biomarkers  measurements  were  also  performed,  such  as
erythrocyte  sedimentation  rate  and  C-reactive  protein.
Results:  The  levels  of  TNF-  and  IL-6  were  higher  in  group  1  (TNF-:  19.4  ±  10.9  pg/ml,  IL-6:
5.75 ±  7  pg/ml)  compared  to  the  other  two  groups,  although  the  difference  was  statistically
signiﬁcant  only  in  the  case  of  TNF-  (group  1:  19.4  ±  10.9  pg/ml,  group  2:  14  ±  4.3  pg/ml Please cite this article as: Hernández-Da Mota SE, Soto-Bahena JJ, Viveros-Sandoval ME, Cardiel-Ríos M. Citoquinas séricas proinﬂama-
orias en retinopatía diabética. Cir Cir. 2015; 83: 100--106.
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and  control:  8.49  ±  3.69  pg/ml,  p  =  0.001).  There  were  no  differences  among  pro-inﬂammatory
biomarkers  such  as  erythrocyte  sedimentation  rate  and  C  reactive  protein.  Among  the  three
groups (p  >  0.05).
Conclusions:  Pro-inﬂammatory  serum  cytokine  levels  were  higher  in  the  diabetes  mellitus  with
diabetic retinopathy  group.  Larger  studies  are  warranted  to  establish  the  real  impact  of  this
ﬁnding.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Citoquinas  séricas  proinﬂamatorias  en  retinopatía  diabética
Resumen
Antecedentes:  Las  citoquinas  proinﬂamatorias  desempen˜an  un  papel  importante  en  la
retinopatía  diabética;  existe  evidencia  contradictoria  sobre  la  elevación  sérica  de  las  mismas
en esta  condición  y  el  posible  rol  que  tienen  como  su  marcador  sérico.
Objetivo:  Evaluar  la  presencia  de  citoquinas  séricas  proinﬂamatorias  en  pacientes  con  y  sin
retinopatía  diabética.
Material  y  métodos: Series  de  casos  comparativas.  Se  incluyeron  36  pacientes  divididos  en  3
grupos: 12  pacientes  con  diabetes  mellitus  con  retinopatía  diabética  (grupo  1),  12  pacientes  con
diabetes mellitus  sin  retinopatía  diabética  (grupo  2)  y  12  pacientes  sin  diabetes  mellitus  como
grupo control.  Se  midieron  los  niveles  séricos  de  las  siguientes  citoquinas  proinﬂamatorias  en
todos los  pacientes:  TNF-,  IL-1  e  IL-6.  También  se  realizó  medición  de  biomarcadores  proin-
ﬂamatorios  o  reactantes  de  fase  aguda,  como  velocidad  de  sedimentación  globular  y  proteína
C reactiva.
Resultados:  Los  niveles  de  TNF-  e  IL-6  resultaron  mayores  en  el  grupo  1  (TNF-:
19.4 ±  10.9  pg/ml,  IL-6:  5.75  ±  7  pg/ml)  comparados  con  los  de  los  otros  2  grupos,  aunque
la diferencia  resultó  estadísticamente  signiﬁcativa  solo  en  el  caso  del  TNF-  (grupo  1:
19.4 ±  10.9  pg/ml,  grupo  2:  14  ±  4.3  pg/ml  y  grupo  control:  8.49  ±  3.69  pg/ml,  p  =  0.001).  No
hubo diferencias  entre  biomarcadores  proinﬂamatorios  como  velocidad  de  sedimentación  glob-
ular y  proteína  C  reactiva  entre  los  3  grupos  (p  >  0.05).
Conclusiones:  Los  niveles  séricos  de  citoquinas  proinﬂamatorias  fueron  mayores  en  el  grupo  1.
Se requieren  mayores  estudios  para  establecer  mejor  el  impacto  de  este  hallazgo.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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The  aethiopathogenesis  of  diabetic  retinopathy  includes  var-
ious  theories,  such  as:  the  aldose  reductase  pathway,1,2
free  radical  tissue  damage3,4 non-enzymatic  protein
glycosylation,5,6 among  others.
One  theory  that  has  gained  importance  in  recent  times
is  related  to  the  concept  that  in  diabetes  and  its  late
complications,  such  as  diabetic  retinopathy,  a  ‘‘low  grade’’
inﬂammation  occurs,  where  pro-inﬂammatory  cytokines
play  an  important  role.7--14 Moreover,  some  of  these
cytokines  tend  to  present  increases  both  at  the  vitreous  cav-
ity  and  serum  levels  in  late  complications  of  diabetes.15 The
above  could  make  them  candidates  to  become  serum  mark-
ers  of  these,  including  diabetic  retinopathy  itself  as  part  of
the  assessment  of  patients.
The  objective  of  this  study  is  to  describe  the  levels  of
some  of  these  cytokines  and  acute  phase  reactants,  in  dia-
betic  patients  with  and  without  retinopathy.
s
n
katerial and methods
he  type  of  study  was  a  comparative  series  of  cases  study.
6  patients  were  chosen  from  General  Hospital  ‘‘Dr.  Miguel
ilva’’  in  the  city  of  Morelia,  Michoacán,  México,  with  simple
andom  sampling,  and  3  study  groups  of  12  patients  each
ere  formed.
The  inclusion  criteria  were:  patients  with  diabetes
ellitus  diagnosis,  patients  with  any  degree  of  diabetic
etinopathy  and  healthy  patients.
Based  on  the  above,  the  ﬁrst  group  was  the  group  of
atients  with  diabetes  mellitus  with  diabetic  retinopathy,
he  second  group  was  of  patients  with  diabetes  mellitus
ithout  diabetic  retinopathy  and  the  third  group  was  of
atients  in  the  control  group.The  exclusion  criteria  were:  patients  with  eye  disease
uch  as  uveitis,  thyroid  disease,  autoimmune  disease,  con-
ective  tissue  or  malignant  disease,  terminal  nephropathy,
nown  cardiac  ischaemic  disease,  chronic  inﬂammatory
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Table  1  Demographic  characteristics,  history,  body  mass  index  and  waist  of  patients  studied.
Variables  measured  DMDR
n  =  12
DMWDR
n  =  12
C
n  =  12
Comparison  amongst  groups
Kruskal--Wallis
Value  of  p
Age  in  years  (X¯  ±  DE) 53.3  ±  14.4 50.7  ±  9.5 51.9  ±  13.2 0.957
Gender (M/F) 4/8  4/8  4/8  1.0
Smoking (%)  8.3  16.7  33.3  0.299
BMI (X¯  ±  DE) 28  ±  4.3 27.4  ±  5 22.7  ±  2 0.001
Waist in  cm  (X¯ ±  DE) 96.5  ±  7  96.2  ±  16.2  78.1  ±  5.5  <  0.0001
C: control group; SD: standard deviation; DMDR: group of diabetes mellitus with diabetic retinopathy; DMWDR: group of diabetes mellitus
without diabetic retinopathy; BMI: body mass index; n: number of patients per group; X¯:  mean.
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Table  2  Degree  of  diabetic  retinopathy  in  patients  of  the
group  with  diabetes  mellitus  and  diabetic  retinopathy.
Degree  of  diabetic  retinopathy
(ETDRS  classiﬁcation)
n  =  12
Non  proliferative  mild  8
Non proliferative  moderate  0
Non proliferative  severe  2
Proliferative  early  2
Proliferative  high  risk  0
ETDRS: Early Treatment Diabetic Retinopathy Study; n: number
m
(
s
d
g
s
i
T
i
r
(
o
[
ﬁ

e
D
T
piseases  (chronic  non-speciﬁc  ulcerative  colitis,  Crohn’s  dis-
ase,  acute  or  chronic  infectious  processes).
Patients  were  subject  to  a  full  ophthalmologic  exami-
ation,  which  included  measuring  corrected  visual  acuity,
iomicroscopy  with  slit  lamp,  tonometry  and  ophthal-
oscopy  with  pharmacological  dilation.
Diabetic  retinopathy  was  classiﬁed  based  on  its  presence
nd  absence  according  to  the  criteria  of  the  Early  Treatment
iabetic  Retinopathy  Study  (ETDRS).
The  demographic  characteristics  of  the  patients  studied
ncluded:  age,  gender,  smoking,  body  mass  index,  waist  cir-
umference,  systemic  arterial  hypertension,  systolic  blood
ressure,  diastolic  blood  pressure,  presence  of  metabolic
yndrome,  (NCEP-ATPIII)  and  risk  of  cardiovascular  event  at
0  years.
This  study  was  approved  by  the  Ethics  Committee  of  Gen-
ral  Hospital  ‘‘Dr.  Miguel  Silva’’,  with  the  informed  consent
f  all  patients  pursuant  to  the  Declaration  of  Helsinki.
amples  and  measurement  of  cytokines
erum  levels  of  cytokines  were  measured  in  all  patients  of
he  3  groups  studied.  Fresh  serum  samples  were  evaluated
sing  ELISA  R&D  kits  (Systems,  Inc.,  Minneapolis,  MN;  and
ndogen,  Rockford,  IL,  USA.).  Cytokines  and  acute  phase
eactants  measured  were:  erythrocyte  sedimentation  rate
mm/h),  c-reactive  protein  (mg/dl),  TNF-, IL-1 and  IL-6
pg/ml).
An  analysis  with  descriptive  statistic  was  carried  out,  and
tandard  deviation  means  were  obtained.  Regarding  infer-
ntial  statistic,  the  Kruskal--Wallis  test  was  used  as  a  global
est  and  the  U  de  Mann--Whitney  test  as  post  hoc  test  for
omparisons  among  speciﬁc  groups.
Regarding  correlation  tests,  Spearman  correlation
oefﬁcients  were  calculated  (Spearman’s  ).
A  p  < 0.05  was  considered  statistically  signiﬁcant.  The
PSS  programme  for  MAC,  version  20  was  used  to  perform
tatistical  tests.
esultss  regards  the  demographic  characteristics,  there  were  no
tatistically  signiﬁcant  differences  among  the  3  groups,  and
here  were  also  no  differences  in  smoking  habits.  The  body
s
a
lof patients.
ass  index  was  normal  on  average  in  the  control  group
Table  1).
In the  stratiﬁcation  of  retinopathy  pursuant  to  the  ETDRS
everity  scale,  the  absence  of  cases  of  high-risk  proliferative
iabetic  retinopathy  stands  out  (Table  2).
The  levels  for  blood  pressure,  metabolic  syndrome,
lucose  serum  levels,  insulin  and  lipid  levels  showed
igniﬁcant  differences  among  the  3  groups  of  patients  stud-
ed  (Tables  3  and  4).
Statistically  signiﬁcant  differences  were  only  found  in
NF-  levels  among  the  3  groups,  with  the  highest  levels
n  the  group  of  patients  with  diabetes  mellitus  with  diabetic
etinopathy  (19.4  ±  10.9  pg)  in  relation  to  the  other  2  groups
those  in  the  group  of  patients  with  diabetes  mellitus  with-
ut  diabetic  retinopathy  [14  ±  4.3  pg]  and  the  control  group
8.49  ±  3.69  pg]  [p  =  0.001])  (Table  5).
There  were  some  statistically  signiﬁcant  correlations:  the
rst  one,  among  the  degree  of  diabetic  retinopathy  and  TNF-
,  as  well  as  between  the  degree  of  retinopathy  and  the
rythrocyte  sedimentation  rate  (Table  6).
iscussion
he  inﬂammatory  theory,  which  is  considered  as  part  of  the
athogenesis  of  diabetic  retinopathy,  has  been  an  intense
ubject  of  worldwide  debate  in  recent  years.9According  to  this  theory,  pro-inﬂammatory  cytokines  play
n  essential  role  in  that  pathogenesis.  Furthermore,  high
evels  of  those  cytokines  have  been  found  both  in  the
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Table  3  Clinicometabolic  and  cardiovascular  risk  variables  in  the  patients  studied.
Variables
measured
DMRD
n  =  12
DMSRD
n  =  12
C
n  =  12
Comparison  amongst  groups
Kruskal--Wallis
Value  of  p
HAS  (%)  41.7  33.3  0  0.049
SBP mmHg
(X¯ ±  DE)
141.8  ±  31.4  117.4  ±  12.2  109.3  ±  8.8  0.007
DBP mmHg
(X¯  ±  DE)
82.9  ±  11.6  77.9  ±  8.7  69  ±  6.5  0.003
Metabolic
syndrome (%)
83.3 83.3 0  <  0.0001
% of  risk  of  car-
diovascular
event  at  10
years
(X¯ ±  DE)
25.4  ±  19  14.5  ±  9.8  6.4  ±  6.1  0.001
C: control group; SD: standard deviation; DMDR: group of diabetes mellitus with diabetic retinopathy; DMWDR: group of diabetes mellitus
without diabetic retinopathy; HAS: hypertension; n: number of patients per group; DBP: diastolic blood pressure; SBP: systolic blood
d
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g
i
g
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tpressure; X¯: mean.
vitreous  cavity  and  blood  in  patients  suffering  from  this  late
complication  of  diabetes.15
As  regards  other  studies  on  this  subject,  Meleth  et  al.15
found  increased  levels  of  some  cytokines  proportional  to  the
severity  of  the  retinopathy,  although  in  their  study,  unlike
in  ours,  there  was  no  control  group  with  healthy  subjects.
Furthermore,  Chen  et  al.16 found  increased  levels  of  IL-
22  in  diabetic  patients  with  retinopathy,  but  also  unlike
our  study,  they  found  no  statistically  signiﬁcant  differences
among  the  group  of  patients  with  retinopathy  and  the  con-
trol  group  in  TNF- levels.  In  line  with  our  ﬁndings,  no
o
f
g
g
Table  4  Laboratory  variables  of  the  patients  studied.  Glycosylate
Variables
measured
DMDR
n  =  12
DMWDR
n  =  12
HbA1c  %
(X¯  ±  DE)
9.1  ±  3  7.1  ±  2.5  
Insulin UI/ml
(X¯  ±  DE)
9.4  ±  5.7  11.4  ±  12.4  
HOMA-IR
(X¯ ±  DE)
4.5  ±  2.6  3.7  ±  3.5  
HDL mg/dl
(X¯ ±  DE)
48  ±  15  47  ±  12.2  
LDL (mg/dl)
(X¯ ±  DE)
135.1  ±  32.1  143.5  ±  46.1  
Triglycerides
mg/dl
(X¯ ± DE)
236.9  ±  162.7  247.9  ±  112.9  
Creatinine,
mg/dl
(X¯ ± DE)
0.9  ±  0.46  0.69  ±  0.19  
C: control group; SD: standard deviation; DMDR: group de diabetes 
mellitus without diabetic retinopathy; HbA1c: glycosylated haemoglob
assessment: insulin resistance; LDL: low-density lipoproteins; n: numbeifferences  among  groups  were  found  in  the  levels  of  IL-6
nd  IL-1. It  is  also  worth  noting  that  they  only  report  2
roups,  one  of  diabetic  patients  but  without  staging  accord-
ng  to  the  diabetic  retinopathy  like  our  study,  and  a control
roup.  On  the  contrary,  the  study  by  Mirza  et  al.17 on  Mexi-
an  population  like  ours,  is  in  line  with  our  study  in  the  sense
hat  they  found  higher  serum  levels  of  TNF-. However,
ne  difference  with  our  ﬁndings  was  that  IL-6  levels  they
ound  had  statistically  signiﬁcant  differences  between  the
roup  of  patients  with  diabetic  retinopathy  and  the  control
roup.
d  haemoglobin,  insulin  levels  and  lipids  proﬁle.
C
n  =  12
Comparison  amongst  groups
Kruskal--Wallis
Value  of  p
4.9  ±  0.75  0.001
4.4  ±  2.3  0.019
0.9  ±  0.5  <  0.0001
55.3  ±  14.2  0.296
126.9  ±  20.4  0.508
119.6  ±  34.3  0.002
0.89  ±  0.32  0.395
mellitus with diabetic retinopathy; DMWDR: group de diabetes
in; HDL: high-density lipoproteins; HOMA-IR: homeostatic model
r of patients per group; X¯:  mean.
104  S.E.  Hernández-Da  Mota  et  al.
Table  5  Comparison  among  the  3  groups  of  serum  levels  of  pro-inﬂammatory  cytokines  and  acute  phase  reactants.
Variables
measured
DMDR
n  =  12
DMWDR
n  =  12
C
n  =  12
Comparison  amongst  groups
Kruskal--Wallis
Value  of  p
ESR  mm/h
(X¯ ±  DE)
25.8  ±  11.2  17.3  ±  14.9  16  ±  12  0.143
CRP mg/L
(X¯ ±  DE)
0.25  ±  0.62  0.33  ±  0.49  0.05  ±  0.17  0.274
TNF- pg/ml
(X¯ ±  DE)
19.4  ±  10.9  14  ±  4.3  8.49  ±  3.69  0.001
IL-1 pg/ml
(X¯  ±  DE)
1  ±  1.14 1  ±  0.7 0.6  ±  0.58 0.329
IL-6 pg/ml
(X¯  ±  DE)
5.75  ±  7 3.8  ±  2 3.87  ±  1.34 0.663
C: control group; SD: standard deviation; DMDR: group of diabetes mellitus with diabetic retinopathy; DMWDR: group of diabetes mellitus
without diabetic retinopathy; IL: interleukin; n: number de patients per group; CRP: C-reactive protein; ESR: erythrocyte sedimentation
rate; TNF-: tumour necrosis factor alpha; X¯:  mean.
Table  6  Statistically  signiﬁcant  correlations  among  the
degree of  severity  of  diabetic  retinopathy  and  SBP,  TNF-,
ESR.
Correlation  ETDRS  SBP  ESR  TNF-
Rho  (Spearman’s  )  0.472  0.390  0.468
Value of  p  0.004  0.019  0.004
ETDRS: Early Treatment Diabetic Retinopathy Study; SBP: sys-
tolic blood pressure; TNF-: tumour necrosis factor alpha; ESR:
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terythrocyte sedimentation rate.
Another  study  with  similar  results  was  carried  out  by
oleva-Georgieva  et  al.18,  who  found  statistically  signiﬁcant
ifferences  in  IL-1 and  IL-6  levels  in  the  group  of  patients
ith  retinopathy.  In  contrast,  our  results  show  that  there
ere  no  differences  in  the  levels  of  these  cytokines.  In  this
tudy,  there  was  staging  of  retinopathy  according  to  severity,
nd  statistically  signiﬁcant  differences  were  found  in  IL-1
nd  TNF- levels  among  the  different  subgroups  of  patients.
ur  results  showed  that  there  was  only  one  signiﬁcant  cor-
elation  in  the  case  of  TNF-.
Doganay  et  al.,  in  their  study  carried  out  also  on  diabetic
atients  and  healthy  controls,  found  a  positive  correlation
mong  some  cytokines  as  sIL-2R,  IL-8,  TNF- (like  in  our
tudy)  and  the  degree  of  diabetic  retinopathy.19
Another  study  proposing  TNF- as  a  serum  marker
or  proliferative  diabetic  retinopathy  is  the  one  carried
ut  by  Gustavsson  et  al.  where  a  statistically  signiﬁcant
orrelation  was  also  found  among  this  degree  of  retinopa-
hy  and  this  cytokine  in  patients  with  type  1  diabetes
ellitus.20 We  also  found  this  correlation,  as  well  as  a
ositive  correlation  between  the  erythrocyte  sedimenta-
ion  rate  and  the  degree  of  retinopathy.  This  is  not  the
ase  with  the  other  pro-inﬂammatory  cytokines  evaluated
erein.
Summing  up,  we  found  the  following  when  comparing
ur  results  with  what  was  reported  in  the  literature9,10,16--20;
n  addition  to  ﬁnding  a  statistically  signiﬁcant  difference
s
t
among  TNF- levels  of  the  different  groups  of  patients
tudied,  it  is  the  ﬁrst  one  to  ﬁnd  a  signiﬁcant  correlation
mong  the  erythrocyte  sedimentation  rate  and  the  degree
f  diabetic  retinopathy.
On  another  note,  one  of  the  limitations  of  our  study  is
hat  there  was  no  calculation  of  the  sample,  which  can
ake  it  prone  to  systematic  type  II  and  type  I  errors;
hat  is  to  say,  that  in  the  case  of  type  I  errors,  statis-
ically  signiﬁcant  differences  can  be  found  when  there
re  actually  none,  and  vice  versa  in  the  case  of  type
I  systematic  errors.  Also,  the  correlations  carried  out
hrough  Spearman’s    may  be  subject  to  this  type  of
ias,  not  compensated  with  this  non-parametric  correlation
est.
An  important  aspect  of  the  results  worth  noting  is  that
he  3  groups  were  balanced  regarding  its  demographical
haracteristics  as  well  as  history  such  as  smoking,  which
s  why  we  can  rule  them  out  as  confusion  factors  in  the
tatistical  analysis.
As  it  was  previously  mentioned,  TNF- was  the  only
ro-inﬂammatory  cytokine  with  a  statistically  signiﬁcant
ifference;  this  is  probably  not  speciﬁc  for  diabetic
etinopathy,  since  the  difference  among  the  groups  of
atients  with  diabetes  mellitus  with  diabetic  retinopa-
hy  and  patients  with  diabetes  mellitus  without  diabetic
etinopathy  was  not  signiﬁcant  in  post  hoc  tests.  However,
here  was  a  statistically  signiﬁcant  correlation  among  the
egree  of  diabetic  retinopathy  in  accordance  with  the  ETDRS
lassiﬁcation  and  TNF- serum  levels  (Spearman’s    =  0.468,
 = 0.004).
The  above  may  be  explained  by  the  fact  that  there
re  other  conditions  associated  in  diabetic  patients,  which
ay  increase  the  levels  of  pro-inﬂammatory  cytokines
uch  as  dyslipidaemia  or  hypertension,  regardless  of  the
resence  of  late  complications  such  as  diabetic  retinopa-
hy.Some  questions  pending  in  relation  to  the  previous
tatement  are,  ﬁrst,  if  there  would  be  some  statis-
ically  signiﬁcant  differences  in  cytokines  serum  levels
mong  the  group  of  patients  with  diabetes  mellitus  and
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diabetic  retinopathy  and  the  group  of  patients  with  diabetes
mellitus  without  diabetic  retinopathy  if  the  sample  size
increases.
Second,  there  is  also  the  question  on  whether  there
would  be  any  difference  in  the  levels  of  pro-inﬂammatory
cytokines  and  acute  phase  reactants  among  the  different
degrees  of  diabetic  retinopathy,  which  remains  unanswered
also  due  to  the  fact  that  the  sample  cannot  detect
it.
Third,  the  TNF- family  is  a  family  of  cytokines  with  a
broad  range  of  isoforms.  It  would  be  interesting,  in  view  of
the  above  and  since  the  levels  of  this  cytokine  were  those
with  statistically  signiﬁcant  differences  in  the  global  test,
to  see  if  some  of  these  isoforms  have  a  higher  sensibility
and  speciﬁcity  in  diabetic  retinopathy  in  relation  with  the
different  degrees  of  severity.
Lastly,  it  would  be  worth  investigating  the  presence  of
higher  levels  of  some  cytokines  according  to  different  ethnic
groups  as  proposed  in  the  study  of  Mirza  et  al.17
All  of  the  above  opens  a  very  wide  ﬁeld  regarding
the  diagnosis  of  diabetic  retinopathy,  with  very  interesting
implications:  there  would  be  a  possibility  of  determining
through  the  increase  of  some  of  these  pro-inﬂammatory
cytokines  and/or  acute  phase  reactants  what  patients
may  have  a  higher  probability  of  suffering  from  dia-
betic  retinopathy  in  the  future,  as  some  authors  have
proposed.21
Conclusion
In  this  study  we  found  statistically  signiﬁcant  differences
among  the  3  groups  of  patients  regarding  TNF- levels,
although  the  difference  among  the  groups  with  diabetes
mellitus  without  diabetic  retinopathy  and  those  with  dia-
betes  mellitus  with  diabetic  retinopathy  in  post  hoc  tests
were  not  conclusive.
The  differences  among  the  levels  of  other  pro-
inﬂammatory  cytokines  were  not  signiﬁcant  among  the  3
groups.
Studies  with  more  subjects,  randomised,  are  necessary
to  determine  more  precisely  the  association  among  the  dif-
ferent  pro-inﬂammatory  cytokines  and  diabetic  retinopathy.
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